HC Wainwright Has Bullish Estimate for RARE Q1 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – HC Wainwright lifted their Q1 2026 earnings estimates for Ultragenyx Pharmaceutical in a research note issued on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn ($1.55) per share for the quarter, up from their previous forecast of ($1.63). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q2 2026 earnings at ($1.20) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($4.05) EPS, Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $1.19 EPS, Q3 2027 earnings at $1.55 EPS, Q4 2027 earnings at $2.64 EPS and FY2027 earnings at $5.66 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The firm had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 566.58% and a negative net margin of 85.54%.The business’s revenue was up 25.5% on a year-over-year basis. During the same period last year, the company posted ($1.39) EPS.

Other equities analysts have also recently issued research reports about the company. Guggenheim lowered their price target on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a report on Monday, January 5th. Wedbush reiterated a “neutral” rating and issued a $25.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday. Jefferies Financial Group dropped their target price on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a report on Tuesday, December 30th. Bank of America decreased their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, January 2nd. Finally, TD Cowen lowered their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Sixteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $68.29.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $20.45 on Thursday. The business has a fifty day moving average price of $25.96 and a two-hundred day moving average price of $29.60. The stock has a market capitalization of $1.97 billion, a PE ratio of -3.50 and a beta of 0.16. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $45.00.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 3,061 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $23.56, for a total transaction of $72,117.16. Following the completion of the transaction, the chief financial officer directly owned 88,935 shares of the company’s stock, valued at $2,095,308.60. This trade represents a 3.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 6,227 shares of company stock valued at $187,126 over the last quarter. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new position in Ultragenyx Pharmaceutical in the second quarter worth approximately $35,765,000. Hsbc Holdings PLC raised its position in shares of Ultragenyx Pharmaceutical by 88.6% during the second quarter. Hsbc Holdings PLC now owns 97,197 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 45,665 shares during the period. Skandinaviska Enskilda Banken AB publ grew its position in Ultragenyx Pharmaceutical by 108.1% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 67,720 shares of the biopharmaceutical company’s stock valued at $2,462,000 after purchasing an additional 35,185 shares during the period. Frazier Life Sciences Management L.P. increased its stake in Ultragenyx Pharmaceutical by 49.3% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 983,715 shares of the biopharmaceutical company’s stock valued at $35,768,000 after purchasing an additional 325,000 shares in the last quarter. Finally, Schroder Investment Management Group increased its stake in Ultragenyx Pharmaceutical by 27.2% during the 2nd quarter. Schroder Investment Management Group now owns 336,173 shares of the biopharmaceutical company’s stock valued at $12,223,000 after purchasing an additional 71,888 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Canaccord lowered its price target to $79 from $128 but maintained a “buy” rating, citing continued upside potential (the new PT implies large upside versus current levels). Canaccord PT Cut
• Positive Sentiment: HC Wainwright cut its target to $50 (from $60) while keeping a “buy” rating, signaling broker confidence in longer‑term value despite lowering near‑term expectations. HC Wainwright Coverage
• Neutral Sentiment: Wedbush reaffirmed a “neutral” rating with a $25 price target, reflecting a more cautious near‑term view and limited upside relative to the current price. Wedbush Note
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Levi & Korsinsky, Robbins LLP, Berger Montague, Bronstein Gewirtz & Grossman, Bragar Eagel & Squire, The Gross Law Firm, Kahn Swick & Foti, Schall Law Firm and others) have filed or are soliciting investors to join a securities‑class action covering purchases from Aug 3, 2023 to Dec 26, 2025 and are urging appointment of a lead plaintiff by April 6, 2026 — this creates legal and financial uncertainty (potential discovery, defense costs, settlement risk). Representative notices: Gross Law Firm Notice Levi & Korsinsky Notice Rosen Law Firm Notice

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.